DBV Technologies (NASDAQ:DBVT) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Wednesday.

Several other research firms have also recently weighed in on DBVT. Zacks Investment Research cut DBV Technologies from a “buy” rating to a “hold” rating in a research report on Friday, September 29th. Citigroup lifted their price objective on DBV Technologies from $43.00 to $57.00 and gave the company a “buy” rating in a research report on Monday, October 2nd. Jefferies Group reiterated a “buy” rating on shares of DBV Technologies in a report on Thursday, August 31st. ValuEngine lowered shares of DBV Technologies from a “hold” rating to a “sell” rating in a report on Tuesday, September 26th. Finally, Leerink Swann lifted their target price on shares of DBV Technologies from $54.00 to $60.00 and gave the company an “outperform” rating in a report on Friday, August 25th. Two analysts have rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $49.63.

Shares of DBV Technologies (DBVT) opened at $21.02 on Wednesday. DBV Technologies has a 12 month low of $20.95 and a 12 month high of $50.57.

Institutional investors and hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC bought a new stake in shares of DBV Technologies during the 2nd quarter valued at $90,724,000. Jennison Associates LLC boosted its holdings in DBV Technologies by 86.4% in the 2nd quarter. Jennison Associates LLC now owns 1,002,067 shares of the company’s stock worth $35,784,000 after buying an additional 464,341 shares during the period. Citadel Advisors LLC bought a new position in DBV Technologies in the 3rd quarter worth $7,794,000. Botty Investors LLC bought a new position in DBV Technologies in the 2nd quarter worth $2,231,000. Finally, Point72 Asset Management L.P. bought a new position in DBV Technologies in the 3rd quarter worth $2,190,000. Institutional investors and hedge funds own 46.94% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://theolympiareport.com/2017/12/06/dbv-technologies-dbvt-downgraded-by-bidaskclub-to-strong-sell.html.

About DBV Technologies

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies SA - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies SA - and related companies with Analyst Ratings Network's FREE daily email newsletter.